Thanh Hoang, MD, Program Director for the Endocrine Fellowship at Walter Reed National Military Medical Center, and Mohamed Shakir, MD, U.S. Navy Captain, National Naval Medical Center discuss a study testing romosozumab in an osteogenesis imperfecta patient.
Osteogenesis imperfecta (OI) is a group of genetic disorders that mainly affect the development of the bones. People with this condition have bones that break easily, often from little or no trauma. However, the severity is different from person to person. People with OI may also have dental problems and hearing loss in adulthood. Other features may include muscle weakness, loose joints, and skeletal malformations. There are various recognized forms of OI which are distinguished by their features and genetic causes.
Dr. Hoang describes a study presented at ENDO 2024 on the efficacy of romosozumab in improving osteoporosis and preventing skeletal fractures in a patient with OI. The study involved a 64-year old patient with OI treated with 210 mg of romosozumab every month. Romosozumab is an FDA approved humanized monoclonal antibody sclerostin inhibitor and is the first anabolic medication that increases bone formation and decreases bone resorption.
Following 12 months of treatment, the patient’s lumbar bone mineral density (BMD) increased by 28.3% and total hip BMD by 7.2%. Also observed was an increase in bone formation markers and a decrease in bone resorption markers. Within the 12 months of treatment, no fracture or severe adverse events occurred.
Chapters:
Osteogenesis Imperfecta Overview 00:00
Current Management 1:47
ENDO 2024 Presentation 2:00
Next Steps 3:09
Benefits of Romosozumab 4:12
8 авг 2024
